Mineralys Therapeutics, Inc. MLYS 深 沪
已收盘 12-19 16:00:00 美东时间
36.82
-0.180
-0.49%
华盛通- 最 高44.13
- 今 开37.35
- 成交量 142.93万股
- 最 低 35.731
- 昨 收 37.00
- 总市值 0
- 52周最高 47.65
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 8.241
- 委 比 -74.67%
- 总股本 --
- 历史最高 47.65
- 量 比 1.08
- 振 幅 22.70%
- 历史最低 1.10
- 每 手 1
- 风险率 12.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Reported Friday, Mineralys Therapeutics Showcases Broad Clinical Potential of Lorundrostat Across Cardio-Renal-Metabolic Diseases
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –– Pivotal Phase 3 Launch-HTN trial featured in the "Best of JAMA and NEJM" session -
11-10 17:42
Uncovering Potential: Mineralys Therapeutics's Earnings Preview
Mineralys Therapeutics (NASDAQ:MLYS) is preparing to release its quarterly earn...
11-07 23:03
Mineralys完成2.5亿美元股票发行定价
美股周三早盘，生物技术公司Mineralys Therapeutics（MLYS）股价下跌2.3%，此前该公司将其规模扩大后的2.5亿美元股票发行价格定为每股25.50美元。此次发行预计于2025年9月4日完成。所筹资金将用于支持公司的增长计划。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
09-03 22:38
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
Mineralys Therapeutics reported positive Phase 2 Explore-CKD trial results, showing lorundrostat 25 mg achieved significant blood pressure reduction and kidney保护 effects in patients with hypertension and CKD, and demonstrated a favorable safety profile. The company plans to discuss results in a conference call.
06-17 11:00
Market-Moving News for March 10th
RKT: -10% | Rocket Companies shares are trading lower after the company announced it will acquire Redfin in an all-stock transaction valued at $12.50 per share. MLYS: 34% | Mineralys Therapeutics shares
03-10 19:29
Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension
– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat
2024-09-25 20:31
HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $30 price target.
2024-08-15 18:01
